Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: GlobeNewswire
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately. “Natarajan has been with Entrada since our inception and his leadership has been invaluable in the research and clinical development of the company’s diverse pipeline of proprietary intracellular therapeutics,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “His deep and broad experience in end-to-end therapeutics development has helped advance our ENTR-601-44 program into the clinic, build our pipeline, and establish a dedicated team driven by intellectual curiosity, teamwork and a commitment to patients and
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of DirectorsBusiness Wire
- Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant ProgramGlobeNewswire
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $25.00 price target on the stock.MarketBeat
- Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
TRDA
Earnings
- 8/13/24 - Beat
TRDA
Sec Filings
- 9/10/24 - Form 4
- 9/10/24 - Form 4
- 9/10/24 - Form 4
- TRDA's page on the SEC website